

**HHS PUBLIC ACCESS**

Author manuscript

JAMA. Author manuscript; available in PMC 2017 September 21.

Published in final edited form as:

JAMA. 2017 March 21; 317(11): 1159–1166. doi:10.1001/jama.2016.21041.

Association Between Direct-to-Consumer Advertising and Testosterone Testing and Initiation in the United States, 2009–2013**J. Bradley Layton, PhD, Yoonsang Kim, MPH, PhD, G. Caleb Alexander, MD, MS, and Sherry L. Emery, MBA, PhD**

Department of Epidemiology, University of North Carolina at Chapel Hill (Layton); NORC at the University of Chicago, Chicago, Illinois (Kim, Emery); Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (Alexander); Departments of Epidemiology and Medicine, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland (Alexander)

Abstract

IMPORTANCE—Testosterone initiation increased substantially in the United States from 2000 to 2013, especially among men without clear indications. Direct-to-consumer advertising (DTCA) also increased during this time.

OBJECTIVE—To investigate associations between televised DTCA and testosterone testing and initiation in the United States.

DESIGN, SETTING, AND POPULATION—Ecologic study conducted in designated market areas (DMAs) in the United States. Monthly testosterone advertising ratings were linked to DMA-

Corresponding Author: J. Bradley Layton, PhD, Department of Epidemiology, University of North Carolina at Chapel Hill, 2104-I McGavran-Greenberg Hall, Campus Box 7435, Chapel Hill, NC 27599-7435 (blayton@unc.edu).

Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Alexander is chair of the FDA's Peripheral and Central Nervous System Advisory Committee, serves as a consultant to a mobile startup to improve patient pain management, serves as a paid consultant to Quintiles IMS Health, and serves on a Quintiles IMS Health scientific advisory board. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies. No other disclosures were reported.

Role of the Funder/Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication.

Meeting Presentation: Portions of this work were presented as a poster at the 31st International Convention on Pharmacoepidemiology and Therapeutic Risk Management; August 2015; Boston, Massachusetts.

Additional Contributions: We thank Yaru Shi, MS, Division of Epidemiology and Biostatistics, School of Public Health, University of Illinois at Chicago, Glen Szczypka, NORC at the University of Chicago, and Dongmei Li, MS, UNC at Chapel Hill, for contributions to data acquisition and management, and Lisa Vera, BA, VeraCite Inc, for assistance with preparation of the manuscript. These contributors did not receive compensation for their roles.

Author Contributions: Dr Layton had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Layton, Kim, Emery.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Layton, Kim, Emery.

Critical revision of the manuscript for important intellectual content: Kim, Alexander, Emery.

Statistical analysis: Layton, Kim, Emery.

Obtained funding: Emery.

Administrative, technical, or material support: Alexander, Emery.

Study supervision: Emery.

level testosterone use data from 2009–2013 derived from commercial insurance claims. Associations between DTCA and testosterone testing, initiation, and initiation without recent baseline tests were estimated using Poisson generalized estimating equations.

EXPOSURES—Monthly Nielsen ratings for testosterone DTCA in the 75 largest DMAs.

MAIN OUTCOMES AND MEASURES—(1) Rates of new serum testosterone testing; (2) rates of testosterone initiation (in-office injection, surgical implant, or pharmacy dispensing) for all testosterone products combined and for specific brands; and (3) rates of testosterone initiation without recent serum testosterone testing.

RESULTS—Of 17 228 599 commercially insured men in the 75 DMAs, 1 007 990 (mean age, 49.6 [SD, 11.5] years) had new serum testosterone tests and 283 317 (mean age, 51.8 [SD, 11.3] years) initiated testosterone treatment. Advertising intensity varied by geographic region and time, with the highest intensity seen in the southeastern United States and with months ranging from no ad exposures to a mean of 13.6 exposures per household. Nonbranded advertisements were common prior to 2012, with branded advertisements becoming more common during and after 2012. Each household advertisement exposure was associated with a monthly increase in rates of new testosterone testing (rate ratio [RR], 1.006; 95% CI, 1.004–1.008), initiation (RR, 1.007; 95% CI, 1.004–1.010), and initiation without a recent test (RR, 1.008; 95% CI, 1.002–1.013). Mean absolute rate increases were 0.14 tests (95% CI, 0.09–0.19), 0.05 new initiations (95% CI, 0.03–0.08), and 0.02 initiations without a recent test (95% CI, 0.01–0.03) per 10 000 men for each monthly ad exposure over the entire period.

CONCLUSIONS AND RELEVANCE—Among US men residing in the 75 designated market areas, regional exposure to televised direct-to-consumer advertising was associated with greater testosterone testing, new initiation, and initiation without recent testing.

The US Food and Drug Administration (FDA) permitted televised direct-to-consumer advertising (DTCA) for prescription medications in 1997. An argument for DTCA is that it may steer consumers to beneficial treatments for high-priority illnesses,¹ but it may also contribute to escalating drug prices and reduced patient safety.² A growing evidence base illustrates strong associations between televised DTCA and increased product prescribing for a variety of indications,^{3–5} and the American Medical Association called for a ban on such marketing in 2015, attempting to reduce prescription costs and curb consumer demand for new, expensive, and potentially inappropriate treatments.⁶

Increased awareness of and demand for a medication may be beneficial if the risk-benefit ratio of the drug is favorable. For many men taking testosterone, that assumption is questionable. Testosterone therapies were originally approved to treat hypogonadism resulting from the disruption of the pituitary-hypothalamus-gonadal axis. Now many men take or are prescribed testosterone for age-related reduced testosterone levels or nonspecific symptoms without pathological hypogonadism. Despite considerable disagreement about the necessity and safety of treatment for these findings and symptoms, testosterone prescribing has increased substantially in the absence of proven new indications,^{7–9} particularly in the United States, where the testosterone initiation rate rose from 20.2 to 75.7 per 10000 person-years from 2000 to 2011.⁸

Although studies have yielded conflicting information on the risks and benefits of testosterone,^{10–13} termination of a clinical trial because of excess adverse cardiovascular effects¹⁴ and observational studies suggesting increased cardiovascular risk^{11,15} led the FDA to reevaluate the risks and revise product labeling requirements in 2014, and pharmaceutical manufacturers, who had previously heavily marketed testosterone products through televised branded, product-specific promotions and unbranded, “low T” awareness advertisements, voluntarily discontinued televised DTCA for testosterone products.

Given the controversies surrounding DTCA and testosterone, we examined the association between exposure to DTCA for testosterone and testosterone testing, initiation, and initiation without a preceding testosterone test.

Methods

This project was approved by the institutional review board of the University of North Carolina at Chapel Hill. Individual consent was not required for this analysis of deidentified data.

Data Sources

Direct-to-Consumer Advertising—We licensed monthly television ratings data from Nielsen Media Research for televised testosterone advertisements in the largest 75 of 210 US designated market areas (DMAs), which are whole, adjoining counties centered around large cities whose populations receive similar television programming. We collected ratings between 2008 and 2013 for both brand-specific prescription testosterone advertisements, which are regulated by the FDA, and nonbranded, condition awareness (“low T”) ads, which are not FDA regulated; we measured DTCA using gross ratings points, a standard metric for quantifying advertising exposure reflecting the percentage of the target audience reached multiplied by frequency of exposures as measured by a combination of electronic metering and surveying across broadcast platforms.^{16,17} We summed gross ratings points within the same DMA and month for all testosterone advertisements and for branded testosterone advertisements and condition awareness ads separately, and divided by 100 to obtain the mean number of times testosterone advertisements were viewed in television households in a given month; an ad with 100 gross ratings points per month can be interpreted as being seen 1 time per month by 100% of the audience, and each 1-unit increase in monthly exposures represented approximately 1 additional viewing of a television ad per household.^{16,18}

Key Points

Question

Is there an association between televised direct-to-consumer testosterone advertising and testosterone testing and initiation in the United States?

Findings

In this ecological study of 75 US designated market areas, each exposure to a testosterone advertisement was associated with monthly relative increases in rates of new testosterone

testing of 0.6%, new initiation of 0.7%, and initiation without a recent baseline test of 0.8%.

Meaning

Regional exposure to televised direct-to-consumer advertising was associated with greater testosterone testing, new initiation, and initiation without recent serum testosterone tests.

Testosterone Testing and Initiation—We used the MarketScan Commercial Claims and Encounters databases (Truven Health Analytics) to quantify population level testosterone testing and initiation (in-office injection, surgical implant, or pharmacy dispensing) within DMAs. The MarketScan databases include individual-level clinical diagnoses, procedures, outpatient prescription dispensing (including from retail, mail-order, and specialty pharmacies), expenditures, and enrollment data paid for by employer sponsored, fee-for-service, fully capitated or partially capitated plans. Claims from employees and their dependents and those with employer-based Medicare supplemental plans also are included. Claims are fully paid and adjudicated, and the research databases are constructed after sufficient time has elapsed to allow for submission, payment, and recording of all outstanding claims. Considerable standardization and quality control activities occur during database construction.¹⁹

We identified men aged 18 years or older residing within defined metropolitan statistical areas (MSAs); 1 or more MSAs make up a DMA. Geographic information was not available for those residing outside MSAs or in smaller micropolitan statistical areas, so our sample focused on those in more urban population centers. Using procedure codes from submitted insurance claims, we identified men newly tested for serum testosterone levels following 6 months without testosterone receipt or testing. Initiation of testosterone gels, patches, injections, or implants was defined as pharmacy dispensing or in-office receipt identified through procedure codes of testosterone following 6 months without prior testosterone receipt. Our main analysis identified initiators of all testosterone products, while subanalyses focused on initiators of individual advertised, branded products (AndroGel [Abbvie Inc] and Axiron [Eli Lilly Inc]). The denominator for monthly rate calculations was the number of adult men enrolled in the MarketScan databases within each MSA on the 15th of each month with at least 6 months of prior continuous enrollment.

We collapsed MSA-level information into DMA levels and linked the data with advertising information.

DMA Characteristics—We collected county-level characteristics and aggregated them into DMAs to account for differences in population demographics, access to health care (measured by physician density), and socioeconomic status (median income). We derived county-level 5-year estimates of age and race/ethnicity distributions from the 2009–2013 American Community Survey, an ongoing yearly survey of US households conducted by the US Census Bureau; race/ethnicity designation was self-reported by choosing from fixed, standard categories. We derived annual estimates of county-level physician density and

median income from the Health Resources and Services Administration's Area Resource File.

Statistical Analysis

We examined the overall pattern of testosterone testing and initiation between 2009 and 2013. We estimated monthly rates of testing and initiation per 10000 men in each DMA and plotted national mean rates with their interquartile ranges. We assessed geographic variation by summing all advertising exposures throughout the study period within DMAs and divided these cumulative measures into 7 approximately equal strata using an equal-distribution (quantizing) algorithm to visualize regional variation in total DTCA; these DTCA levels were mapped across the United States by year to observe changes in geographic variation over time.

We describe the association between DTCA and testosterone testing and initiation using adjusted rate ratios (RRs) and 95% confidence intervals derived from multivariable Poisson models with generalized estimating equations²⁰ to account for clustering within DMAs over time; we used an autoregressive (AR-1) correlation structure. Direct-to-consumer advertising exposures were included as a continuous variable; thus, the resulting RRs indicate the association between a 1-unit increase in ad exposures and testosterone rates. Monthly advertising data (November 2008 to October 2013) were linked to monthly testosterone data 2 months in the future, allowing for the passage of time between viewing an ad, seeking care, and receiving treatment. To observe the effect of varied lag times, we performed a preplanned sensitivity analyses evaluating a 1-month lag and a post hoc analysis of a 3-month lag.

We adjusted the models for age (proportion of population in age groups of 35–44, 45–54, 55–64, 65–74, and ≥75 years, included in model as 5 variables), race (proportion of white and black population, included in model as 2 variables), physician density, socioeconomic status (included in model as a quadratic trend of median income because increases in income may be more meaningful for medication use at lower income values), seasonality (modeled with 4 variables, 1 for each season, each taking a 0 or 1 value), and overall increasing usage time trend⁸ to facilitate estimation of the increases in testosterone testing and initiation within a DMA not due to expected seasonal variation or overall national trends. We modeled time trends with cubic splines to allow for flexibility at nodes corresponding to key events: FDA warning of testosterone gel transfer from men to women and children²¹ (May 2009); release and approval of new testosterone gel formulations^{22,23} (April 2011); and National Institutes of Health funding of observational studies of the cardiovascular safety of testosterone products²⁴ (August 2012).

Our primary exposure variable was total monthly testosterone advertising exposures, but we additionally investigated individual branded advertisements and unbranded condition awareness advertisements from 2012 to 2013; prior to 2012, there were primarily only unbranded “low T” condition awareness advertisements. We estimated the association of advertising with (1) new serum testosterone tests; (2) all new testosterone initiations, including branded and unbranded patch, gel, injection, and implanted formulations; (3) initiation without a recent test; and (4) product-specific initiation of branded testosterone

gels. Model-based predicted rates were plotted against observed testosterone rates to evaluate model fit. As post hoc sensitivity analyses we investigated the associations in each year alone because there was substantial variation in advertising intensity by year and more diverse advertising, greater competition, and plateaued overall use during later years, and we explored nonlinear relationships by modeling DTCA with both a linear and a quadratic term.

We compared RR estimates from different periods and sensitivity analyses using ratios of RRs.²⁵ We considered a 2-sided threshold of $P < .05$ to be statistically significant. All analyses were conducted using SAS software, version 9.4 (SAS Institute Inc).

Results

Of 17 228 599 unique men across the 75 DMAs (mean age, 42.8 [SD, 16.0] years), 1 007 990 (mean age, 49.6 [SD, 11.5] years) had new serum testosterone tests and 283 317 (mean age, 51.8 [SD, 11.3] years) initiated testosterone treatment during the study period (59% initiated testosterone gels, 36% injections, 3% patches, and 2% implants). Baseline DMA characteristics (Table 1) and testosterone use varied widely, with DMA level testing rates ranging from 2.7 (95% CI, 0.7–7.3) to 30.5 (95% CI, 26.0–35.7) per 10000 men and initiation rates ranging from 0.6 (95% CI, 0.1–1.9) to 23.2 (95% CI, 5.9–63.0) per 10000 men (Table 1; see eTable 1 in the Supplement for DMA-level characteristics by year).

Descriptive Trends of Testosterone Testing and Initiation

Monthly testosterone testing and initiation increased between 2009 and 2012 prior to decreasing through 2013 (Figure 1, A and B); initiation without a recent baseline test decreased slightly but consistently over the period. After introduction of Axiron in 2011, Androgel initiation rates increased and then decreased in 2012–2013 (Figure 1C). Mean monthly rates per 10000 men were 24.6 (SD, 9.5) for testosterone testing, 7.6 (SD, 3.8) for testosterone initiation, and 2.4 (SD, 1.5) for testosterone initiation without prior testing.

Descriptive Trends of Testosterone DTCA

Direct-to-consumer advertising exposure increased over the period with substantial variation, ranging from months without any advertising to a mean 13.6 (SD, 0.8) monthly household exposures in December 2012 (Figure 2A). Prior to 2012, Abbvie-funded, unbranded “low T” advertisements were the primary form of advertising. Following the introduction of Axiron and a more concentrated Androgel formulation in 2011, more branded, product-specific advertising emerged and unbranded condition awareness advertisements decreased (Figure 2B).

Television advertising intensity varied by DMA region, with cumulative exposures ranging from 154.9 to 203.5 advertisement exposures per DMA over the study period (mean, 179.1; SD, 10.0). The most concentrated advertising occurred in the Southeast and the southern Great Lakes regions (Figure 3), a geographic focus consistent through most of the study period (eFigure 1 in the Supplement).

Association of DTCA and Testosterone Testing and Initiation

Increases in advertisement exposure were associated with higher rates of testosterone testing, initiation, and initiation without testing (Table 2), except Axiron initiation, which was introduced later in the period and had lower overall use (Table 2; see eTable 2 and eFigure 2 in the Supplement for model goodness-of-fit estimates). Each additional ad exposure was associated with a relative 0.6% (95% CI, 0.4%–0.8%) increase in testing, 0.7% (95% CI, 0.4%–0.10%) increase in initiation, and 0.8% (95% CI, 0.2%–0.13%) increase in initiation of testosterone without baseline testing, corresponding to absolute monthly increases of 0.14 new tests (95% CI, 0.09–0.19), 0.05 initiations (95% CI, 0.03–0.08), and 0.02 initiations without baseline testing (95% CI, 0.01–0.03) per 10 000 men across the study period.

Prior to 2012, advertising—almost all of which was unbranded “low T” advertising—was associated with testosterone testing (RR, 1.012; 95% CI, 1.009–1.014) and initiation (RR, 1.012; 95% CI, 1.007–1.017); after 2012, the advertising was primarily branded, but associations with testing (RR, 0.998; 95% CI, 0.995–1.001) or initiation (RR, 0.998; 95% CI, 0.994–1.003) were no longer statistically significant (ratios of RRs in 2012–2013 vs 2009–2011, 0.986 [95% CI, 0.982–0.990]; $P < .001$ for testing and 0.986 [95% CI, 0.980–0.993]; $P < .001$ for initiation, suggesting a statistically significant difference in association between the periods). Androgel was the most widely used branded product during the entire study period and the most widely advertised branded product after 2012; its advertising was associated with increased rates of testing and initiation across all domains (Table 2). However, other advertising types showed a more attenuated or no association in 2012 and 2013.

When exploring nonlinear relationships between DTCA and testosterone by modeling with a quadratic term, we observed a “saturation effect” wherein the association between a 1-unit increase in DTCA exposure and testosterone became weaker at higher levels of DTCA (eTable 4 in the Supplement). For example, when a DMA’s monthly exposure increased from 1 to 2, the association between the increase in DTCA with new testing was an RR of 1.015 (95% CI, 1.012–1.019); from 5 to 6, an RR of 1.012 (95% CI, 1.009–1.014); and from 10 to 11, an RR of 1.007 (95% CI, 1.005–1.009).

There were no statistically significant associations between DTCA and testosterone testing and initiation in sensitivity analyses testing 1- and 3-month lag periods (eTable 5 in the Supplement).

Discussion

Increasing televised DTCA for testosterone therapies was observed across US metropolitan areas between 2009 and 2013, and both branded and condition awareness ads were associated with increased testosterone testing and initiation. Although the average increase in testosterone rates associated with a single ad exposure was less than 1%, advertisements were widespread and frequent during the study period; with cumulative ad exposures of close to 200 in some DMAs, DTCA was associated with substantial overall increases in testosterone testing and initiation.

These associations were strongest when only a single brand was being advertised, and there may have been a saturation effect, as DTCA was more prevalent during 2012 and 2013 than earlier periods, yet with increasing safety concerns, introduction of new formulations, and competing advertising campaigns, testosterone use decreased somewhat and the associations of DTCA with testing or initiation became attenuated (eTable 3 and eTable 4 in the Supplement). Additionally, DTCA was associated with more initiation of testosterone without recent serum testing, contrary to treatment guidelines.²⁶

These findings illustrate the association between mass marketing efforts and demand for a prescription drug in a context in which it has been widely overused.^{7,8} Ultimately, prescribing decisions rest with physicians, but patient preferences and requests for specific medications influence prescribing decisions,²⁷⁻²⁹ and DTCA may be associated with increased patient demand. While other studies have demonstrated associations between DTCA and increasing medication use, this study demonstrates increases in potentially inappropriate use and increasing initiation during a time when most testosterone use was of questionable value for age-related testosterone decreases without strong evidence of benefit. Characterizing the role of DTCA in promoting testosterone initiation among a large segment of middle-aged and older men for nonspecific symptoms and age-related declines in testosterone levels is relevant to ongoing policy debates regarding DTCA. This study complements many others that suggest the contribution that DTCA may make in the early adoption of recently approved treatments whose risk-benefit profile may be quite unclear.²

Furthermore, concerns remain regarding the safety and benefit of using testosterone to treat age-related declines in testosterone levels. Original FDA approval of testosterone formulations was based on trials demonstrating increased testosterone blood levels among men with specific disorders of the testes or pituitary, not amelioration of any clinical symptoms.³⁰ A recent study on the benefits of raising testosterone levels among older men with low testosterone but without pathological hypogonadism found moderate improvements in sexual function and mood but no benefit in vitality or walking distance³¹; this may reignite the cost-benefit discussion, yet the trials were too small to evaluate safety, and they offer little support for widespread use of testosterone outside the narrow approved indications. Although the current study lacks individual-level information on patients' indications for treatment, much of the increase in testosterone use in the United States has been among men being treated for age related decreases in testosterone or nonspecific symptoms.⁸

This study has limitations. As an ecologic study, it lacks information on individual-level DTCA exposures. Some individuals residing near DMA boundaries may view televised ads outside their assigned DMA. For pharmacy-dispensed products, the study assessed receipt from the pharmacy, not actual use by patients. Although there were no explicitly missing data from any data source, the findings may underestimate true testosterone testing and initiation if tests or prescriptions were not submitted to insurers for reimbursement. Additionally, the Market Scan data bases contain information only on those with employer-sponsored health insurance in the United States; these results may not be generalizable to men covered by public insurance plans or uninsured men. This analysis was limited to investigating geographic variation in televised pharmaceutical advertising; there may be

additional forms of influential promotion, such as physician-targeted promotion, internet advertising (including branded ads and unbranded disease awareness symptom quizzes), or advertisements by men's health specialty clinics, thus potentially over attributing some testosterone use to televised DTCA. While televised DTCA is the most common and influential type of direct-to-consumer advertising medium,^{32,33} internet advertising was also widespread throughout most of the study period, although it likely lacks the geographic variation of televised DTCA. However, televised DTCA was consistently associated with multiple dimensions of testosterone use. Finally, the statistically significant associations between DTCA and testosterone testing and initiation we report at 2 months were not apparent in sensitivity analyses testing of 1- and 3-month lag periods; the reasons for the dependence of the association on the 2-month lag period are not knowable from our data.

Conclusions

Among US men residing in 75 US DMAs, regional exposure to televised DTCA was associated with greater testosterone testing, new initiation, and initiation without recent testing.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Funding/Support: This project was funded by grants from the National Institute on Aging (grant R01 AG042845) and the National Heart, Lung, and Blood Institute (grant R01 HL107345). The database infrastructure used for this project was funded by the Department of Epidemiology, University of North Carolina (UNC) Gillings School of Global Public Health; the Cecil G. Sheps Center for Health Services Research, UNC; the CER Strategic Initiative of UNC's Clinical Translational Science Award (grant 1 ULI RR025747); and the UNC School of Medicine.

References

1. Almasi EA, Stafford RS, Kravitz RL, Mansfield PR. What are the public health effects of direct-to-consumer drug advertising? *PLoS Med.* 2006; 3(3):e145. [PubMed: 16563041]
2. Brody H, Light DW. The inverse benefit law: how drug marketing undermines patient safety and public health. *Am J Public Health.* 2011; 101(3):399–404. [PubMed: 21233426]
3. Daubresse M, Hutfless S, Kim Y, et al. Effect of direct-to-consumer advertising on asthma medication sales and healthcare use. *Am J Respir Crit Care Med.* 2015; 192(1):40–46. [PubMed: 25879303]
4. Avery RJ, Eisenberg MD, Simon KI. The impact of direct-to-consumer television and magazine advertising on antidepressant use. *J Health Econ.* 2012; 31(5):705–718. [PubMed: 22835472]
5. Kim Y, Kornfield R, Shi Y, et al. Effects of televised direct-to-consumer advertising for varenicline on prescription dispensing in the United States, 2006–2009. *Nicotine Tob Res.* 2016; 18(5):1180–1187. [PubMed: 26385926]
6. American Medical Association. [Accessed March 30, 2016] AMA calls for ban on DTC ads of prescription drugs and medical devices [press release]. Nov 17. 2015 <https://www.ama-assn.org/content/ama-calls-ban-direct-consumer-advertising-prescription-drugs-and-medical-devices>
7. Handelsman DJ. Global trends in testosterone prescribing, 2000–2011: expanding the spectrum of prescription drug misuse. *Med J Aust.* 2013; 199(8):548–551. [PubMed: 24138381]

8. Layton JB, Li D, Meier CR, et al. Testosterone lab testing and initiation in the United Kingdom and the United States, 2000 to 2011. *J Clin Endocrinol Metab.* 2014; 99(3):835–842. [PubMed: 24423353]
9. Bjerkeli PJ, Mulinari S, Merlo J. Testosterone prescribing in the population—a short social epidemiological analysis in Sweden. *Pharmacoepidemiol Drug Saf.* 2016; 25(1):11–15.
10. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. *J Clin Endocrinol Metab.* 2010; 95(2):639–650. [PubMed: 20061435]
11. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. *JAMA.* 2013; 310(17):1829–1836. [PubMed: 24193080]
12. Wang C, Cunningham G, Dobs A, et al. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. *J Clin Endocrinol Metab.* 2004; 89(5):2085–2098. [PubMed: 15126525]
13. Onasanya O, Iyer G, Lucas E, Lin D, Singh S, Alexander GC. Association between exogenous testosterone and cardiovascular events: an overview of systematic reviews. *Lancet Diabetes Endocrinol.* 2016; 4(11):943–956. [PubMed: 27669646]
14. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. *N Engl J Med.* 2010; 363(2):109–122. [PubMed: 20592293]
15. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. *PLoS One.* 2014; 9(1):e85805. [PubMed: 24489673]
16. Szczypka, G., Emery, S., Wakefield, MA., Chaloupka, FJ. [Accessed February 21, 2017] The Adaptation and Use of Nielsen Media Research Commercial Ratings Data to Measure Potential Exposure to Televised Smoking-Related Advertisements. May. 2003 impacTEEN Research Paper Series No. 29. http://impacteen.uic.edu/generalarea_PDFs/Nielsenpaper_051403.pdf
17. Nielsen. [Accessed December 20, 2016] TV ratings. <http://www.nielsen.com/us/en/solutions/measurement/television.html>
18. Kornfield R, Alexander GC, Qato DM, Kim Y, Hirsch JD, Emery SL. Trends in exposure to televised prescription drug advertising, 2003–2011. *Am J Prev Med.* 2015; 48(5):575–579. [PubMed: 25891057]
19. Hansen, LG., Chang, S. White Paper: Health Research Data for the Real World: The MarketScan Databases. Ann Arbor, MI: Truven Health Analytics; 2012. http://truvenhealth.com/portals/0/assets/PH_11238_0612_TEMP_MarketScan_WP_FINAL.pdf [Accessed February 23, 2017]
20. Liang K-Y, Zeger SL. Longitudinal data analysis using generalized linear models. *Biometrika.* 1986; 73(1):13–22.
21. US Food and Drug Administration. [Accessed December 25, 2016] Testosterone gel safety concerns prompt FDA to require label changes, medication guide [press release]. May 7. 2009 <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149580.htm>
22. Eli Lilly and Co. [Accessed December 26, 2016] Axiron (testosterone) topical solution CIII now available in pharmacies [press release]. Apr 1. 2011 <https://investor.lilly.com/releasedetail2.cfm?releaseid=561425>
23. US Food and Drug Administration. [Accessed December 26, 2016] AndroGel (testosterone gel) 1.62%. Nov 17. 2011 http://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022309_androGel_toc.cfm
24. US Department of Health and Human Services. [Accessed December 26, 2016] Analysis of databases from health care systems or large epidemiologic studies to evaluate safety of testosterone administration in older men (R01). <https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-12-007.html>
25. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. *BMJ.* 2003; 326(7382):219. [PubMed: 12543843]

26. Bhasin S, Cunningham GR, Hayes FJ, et al. Task Force, Endocrine Society. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2010; 95(6):2536–2559. [PubMed: 20525905]
27. McKinlay JB, Trachtenberg F, Marceau LD, Katz JN, Fischer MA. Effects of patient medication requests on physician prescribing behavior: results of a factorial experiment. *Med Care.* 2014; 52(4):294–299. [PubMed: 24848203]
28. Kravitz RL, Epstein RM, Feldman MD, et al. Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial. *JAMA.* 2005; 293(16):1995–2002. [PubMed: 15855433]
29. Liu Q, Gupta S. The impact of direct-to-consumer advertising of prescription drugs on physician visits and drug requests: empirical findings and public policy implications. *Int J Res Mark.* 2011; 28(3):205–217.
30. US Food and Drug Administration. Joint Meeting for Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) and the Drug Safety and Risk Management Advisory Committee (DSARM AC). College Park, MD: US Food and Drug Administration; 2014.
31. Snyder PJ, Bhasin S, Cunningham GR, et al. Testosterone Trials Investigators. Effects of testosterone treatment in older men. *N Engl J Med.* 2016; 374(7):611–624. [PubMed: 26886521]
32. Dijkstra M, Buijtels HEJMM, van Raaij WF. Separate and joint effects of medium type on consumer responses: a comparison of television, print, and the internet. *J Bus Res.* 2005; 58(3):377–386.
33. FiercePharma. [Accessed August 19, 2016] Top 10 drug advertising spends—Q1. 2012. <http://www.fiercepharma.com/special-report/top-10-drug-advertising-spends-q1-2012>




Figure 1. Mean Testosterone Testing and Initiation Rates Among Adult Men in the 75 Largest Designated Market Areas in the United States, January 2009–December 2013. Shaded areas are interquartile ranges. Vertical dotted lines in all panels indicate 3 key events that may be associated with overall use: (1) May 2009, US Food and Drug Administration warning of transfer of testosterone gel from men to women and children; (2) April 2011, release of new testosterone gel formulations; and (3) August 2012, increased concern about

cardiovascular safety of testosterone products as evidenced by the National Institutes of Health funding safety studies of testosterone in older men.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2.
 Mean Household Testosterone Advertisement Exposures From Nielsen Television Ratings
 Across the 75 Largest Designated Market Areas in the United States, November 2008–
 October 2013
 Shaded areas are interquartile ranges.




Figure 3. Geographic Distribution of Cumulative Testosterone Advertisement Exposures From Nielsen Television Ratings (Total Summed Ratings, November 2008–October 2013) in the 75 Largest US DMAs

Monthly advertisement exposures were summed across the entire study period within designated market areas (DMAs), and DMAs were stratified into 7 strata of cumulative advertising exposures containing approximately equal numbers of DMAs. The borders between exposure strata were defined empirically; thus, there are gaps between strata where no DMA had measures in that range.

Table 1

Characteristics of 75 DMAs, January 2009

DMA Characteristics	Estimate
Enrollees per DMA, median (IQR) ^a	45 501 (23 311–74 815)
Age, mean (SD) % in category, y ^b	
35–39	6.30 (0.51)
40–44	6.71 (0.41)
45–49	7.13 (0.39)
50–54	7.26 (0.44)
55–59	6.46 (0.48)
60–64	5.58 (0.53)
65–69	4.14 (0.55)
70–74	3.11 (0.51)
75	6.21 (1.30)
Race, mean (SD) % in category ^b	
White	77.2 (11.6)
Black	12.2 (8.7)
Physician density/10 000 men, mean (SD) ^c	22.7 (5.1)
Mean (SD) of median household income, \$ ^c	45 757 (8401)

Abbreviations: DMA, designated market area; IQR, interquartile range.

^aData on adult male enrollees are from Truven Health Analytics MarketScan databases, defined as adult men enrolled in the MarketScan database residing in the DMA on the 15th of the month with 6 months of previous enrollment.

^bData on age and race distributions are from the US Census American Communities Survey.

^cData on income and physician density are from the Health Resources and Services Administration's Area Resource File.

Table 2

Association of Monthly Testosterone Direct-to-Consumer Advertising With Testosterone Testing and Initiation Among US Men Living in the 75 Largest Designated Market Areas^a

Testosterone Measure	Years	Base Testosterone Rate Per 10 000 Men, Mean (SD) ^b	Advertising Type	Association of 1-Unit Increase in Advertising Exposures With Testosterone Testing or Initiation, Rate Ratio (95% CI)
Testing	2009–2013	18.6 (6.2)	Total, any ads	1.006 (1.004–1.008)
	2009–2011	18.6 (6.2)	Total, any ads ^c	1.012 (1.009–1.014)
	2012–2013	29.4 (9.4)	Total, any ads	0.998 (0.995–1.001)
	2012–2013	29.4 (9.4)	“Low T” disease awareness	1.046 (1.038–1.054)
	2012–2013	29.4 (9.4)	AndroGel, branded	1.001 (0.997–1.006)
	2012–2013	29.4 (9.4)	Axiron, branded ^d	0.995 (0.983–1.007)
Initiation	2009–2013	6.4 (3.4)	Total, any ads	1.007 (1.004–1.010)
	2009–2011	6.4 (3.4)	Total, any ads ^c	1.012 (1.007–1.017)
	2012–2013	8.8 (4.3)	Total, any ads	0.998 (0.994–1.003)
	2012–2013	8.8 (4.3)	“Low T” disease awareness	1.055 (1.043–1.066)
	2012–2013	8.8 (4.3)	AndroGel, branded	1.001 (0.996–1.007)
	2012–2013	8.8 (4.3)	Axiron, branded ^d	0.999 (0.985–1.012)
Initiation without testing	2009–2013	2.9 (2.7)	Total, any ads	1.008 (1.002–1.013)
	2009–2011	2.9 (2.7)	Total, any ads ^c	1.013 (1.004–1.022)
	2012–2013	2.5 (1.5)	Total, any ads	0.995 (0.986–1.004)
	2012–2013	2.5 (1.5)	“Low T” disease awareness	1.055 (1.035–1.076)
	2012–2013	2.5 (1.5)	AndroGel, branded	0.996 (0.987–1.006)
	2012–2013	2.5 (1.5)	Axiron, branded ^d	1.006 (0.989–1.024)
AndroGel initiation	2009–2013	3.0 (1.4)	Total, any ads	1.008 (1.003–1.013)
	2009–2011	3.0 (1.4)	Total, any ads ^c	1.017 (1.009–1.025)
	2012–2013	3.5 (1.6)	Total, any ads	0.995 (0.989–1.001)
	2012–2013	3.5 (1.6)	“Low T” disease awareness	1.034 (1.017–1.052)
	2012–2013	3.5 (1.6)	AndroGel, branded	1.001 (0.994–1.008)
	2012–2013	3.5 (1.6)	Axiron, branded ^d	0.977 (0.962–0.992)
Axiron initiation	2009–2013	0.0 (0.0)	Total, any ads	0.998 (0.992–1.004)
	2012–2013	0.5 (0.5)	Total, any ads	1.011 (0.994–1.027)
	2012–2013	0.5 (0.5)	“Low T” disease awareness	1.074 (1.046–1.103)
	2012–2013	0.5 (0.5)	AndroGel, branded	1.004 (0.987–1.022)
	2012–2013	0.5 (0.5)	Axiron, branded ^d	1.035 (0.964–1.111)

^aSource: Truven Health Analytics MarketScan databases, Nielsen television ratings, 2009–2013. The rate ratio and 95% confidence interval (95% CI) of mean rates was derived from rate ratio estimates from Poisson generalized estimating equation regression adjusting for income, race/ethnicity, age, physician density, overall time trend, and seasonality. Testosterone ad exposures was included as a continuous variable, and the rate ratios estimate the association between a 1-unit increase in ad exposure and the testosterone rate; for example, across the entire study period, 1 exposure to a testosterone advertisement was associated with a 0.7% higher subsequent initiation rate (rate ratio, 1.007; 95% CI, 1.004–1.010),

corresponding to a mean absolute increase of 0.05 initiations (95% CI, 0.03–0.07) per 10 000 men per ad. However, the mean number of ad exposures per month was 2.9 (SD, 2.8), which was associated with a 2.0% higher subsequent initiation rate (rate ratio, 1.020; 95% CI, 1.011–1.029) and a mean absolute increase of 0.15 initiations (95% CI, 0.09–0.22) per 10 000 men.

^bRate during the first month of the considered period.

^cPrior to 2012, almost all recorded advertisements were unbranded disease awareness ads.

^dModels restricted to the months following the beginning of Axiron-branded advertising (December 2011).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript